Maravai LifeSciences shares surge 10.04% intraday after CEO buys $1.5 million in shares.

Maravai LifeSciences Holdings Inc. rose 10.04% intraday after its CEO purchased $1.5 million in shares, signaling confidence in the company’s long-term prospects tied to the expansion of mRNA technology applications. The insider buying, coupled with the firm’s strategic focus on mRNA innovation—a sector gaining momentum amid evolving therapeutic and vaccine opportunities—likely drove the sharp intraday rally. The move reflects optimism about Maravai’s positioning in a high-growth biotech segment and reinforces investor sentiment around its future potential.